The January 2026 biopharma market outlook makes the case for optimism, citing scaled innovation, supportive valuations, strong M&A momentum, and improving capital markets—trends clearly reflected in biopharma deal and licensing activity tracked by DealForma. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
